Favard C, Ortega N, Bayard F, Plouet J
Service d'Ophtalmologie, Hôtel-Dieu, Paris, France.
Diabetes Metab. 1996 Jul;22(4):268-73.
Since the pioneer work of Michaelson in 1947 reporting that retinal ischemia induces the release of soluble angiogenic compounds, numerous studies have been conducted to identify the molecular structure of such messengers. In the early 1980s, the deciphering of angiogenic factor-signaling pathways and their description in the retina focused attention on growth factors. Vascular endothelial growth factor, the major candidate identified in 1992, induces in vivo angiogenesis and vascular permeability. Its expression is enhanced in vitro by hypoxia and hypoglycaemia; and its immunoreactivity is increased in diabetic patients. A decrease in its bioavailability reduces the intensity of neovascularization.
自1947年迈克尔逊的开创性研究报告称视网膜缺血会诱导可溶性血管生成化合物的释放以来，人们进行了大量研究以确定此类信使分子的分子结构。在20世纪80年代早期，血管生成因子信号通路的破译及其在视网膜中的描述使人们将注意力集中在生长因子上。血管内皮生长因子是1992年确定的主要候选因子，可诱导体内血管生成和血管通透性。其表达在体外因缺氧和低血糖而增强；在糖尿病患者中其免疫反应性增加。其生物利用度的降低会降低新生血管形成的强度。
